Get started
Author

Mita Puspita

Observed name: M. Puspita
ORCID: 0000-0001-9980-2131
Observed ORCID: 0000-0001-9980-2131
OpenAlex ID: A5050729780
The Predictive Diagnostic Value of Serial Daily Bedside Ultrasonography for Severe Dengue in Indonesian Adults
2013 · Meta Michels, Uun Sumardi, et al. · PLoS neglected tropical diseases · 61
PDF
Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine
2019 · Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, et al. · PLoS ONE · 27
PDF
New parameters available on Sysmex XE ‐5000 hematology analyzers contribute to differentiating dengue from leptospirosis and enteric fever
2015 · A. Oehadian, M. Michels, et al. · International Journal of Laboratory Hematology · 24
West Nile Virus Documented in Indonesia from Acute Febrile Illness Specimens
2014 · Khin Saw Aye Myint, Herman Kosasih, et al. · American Journal of Tropical Medicine and Hygiene · 23
Decreased plasma levels of the endothelial protective sphingosine-1-phosphate are associated with dengue-induced plasma leakage
2015 · Meta Michels, Lukasz Japtok, et al. · Journal of Infection · 21
One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine
2020 · Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, et al. · International Journal of Infectious Diseases · 17
PDF
A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report
2020 · Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, et al. · BMC Pediatrics · 15
PDF
Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia
2022 · Yetty M. Nency, Farid Agung Rahmadi, et al. · Clinical and Experimental Vaccine Research · 4
Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study
2025 · Yetty Movieta Nency, Rini Sekartini, et al. · Human Vaccines & Immunotherapeutics · 3
PDF
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults
2024 · Kusnandi Rusmil, Eddy Fadlyana, et al. · Vaccines · 3
A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity
2024 · Sukamto Koesnoe, Bernie Endyarni Medise, et al. · Tropical Diseases Travel Medicine and Vaccines · 3
PDF
One-month evaluation of safety and immunogenicity of a Vi-DT typhoid conjugate vaccine (Bio-TCV®) in Indonesian subjects 6 months to 45 years: A phase III randomized clinical trial
2025 · Bernie Endyarni Medise, I. Gusti Ayu Trisna Windiani, et al. · Vaccine X · 2
Safety profile of Td vaccination in Indonesian pregnant women: a post-marketing surveillance study
2019 · Hindra Irawan Satari, Mita Puspita, et al. · Medical Journal of Indonesia · 2
PDF
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents
2024 · Eddy Fadlyana, Kusnandi Rusmil, et al. · Vaccines · 1
PDF
Immunogenicity and safety of SARS-COV-2 recombinant protein subunit vaccine (INDOVAC) in west Sumatera Province adolescents: A phase 3, observer blind, randomized, active-controlled
2026 · Asrawati Nurdin, Bernie Endyarni Medise, et al. · Vaccine X
PDF
Works count: 16
Citation count: 206
H-index: 7
I10-index: 7
Year
Topic
Type